Overview

A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants

Status:
Recruiting
Trial end date:
2024-12-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine recommended Phase 2 dose (RP2D) regimen(s) of JNJ-75229414 in Part 1 (Dose Escalation and to determine safety at the RP2D regimen(s) in Part 2 (Dose Expansion).
Phase:
Phase 1
Details
Lead Sponsor:
Janssen Research & Development, LLC